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ABSTRACT 
Effect of conjugated linoleic acid on the regulation of feed intake and body fat in the short 
term 
Valerie J. Shelton 
 
Conjugated linoleic acid (CLA) is known to decrease feed intake and body fat in mice. Our 
objectives were to determine the incorporation of CLA into tissues and the effect on serum 
hormones and arcuate neuropeptides during the first 7 d of CLA consumption. Mice (n=150; 9-
wk-old) were fed 0 (ad libitum or pair-fed to CLA-fed mice) or 2% CLA (ad libitum) for 1, 2, 3, 
5, or 7 d. A body fat index was calculated; liver, adipose tissue, and brain were analyzed for fatty 
acid profiles; and serum insulin, leptin, and PYY were measured. CLA and pair-fed mice ate less 
(P< 0.05) than control mice on d 1, 2, 3, and 7, but CLA-fed mice were leaner than control mice 
only on d 7 (P< 0.01). CLA was detected in adipose tissue starting on d 2 and in liver on d 1, but 
CLA was not detectable in the brain. Serum insulin was increased in CLA-fed mice on day 5 
(P<0.01) and 7 (P<0.05), and serum leptin was reduced (P<0.05) in CLA-fed mice compared to 
control mice on d 7. Serum PYY tended (P=0.07) to increase in CLA-fed mice on d 1 and 3. 
NPY was decreased (P<0.05) in CLA-fed mice compared to PF on d 7. The CLA-induced 
reduction in feed intake is not sufficient to cause the loss of body fat as pair-fed mice were not 
leaner than controls. The lack of CLA in the brain indicates that the effect on feed intake may 
indirect. 
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CHAPTER 1:  REVIEW OF LITERATURE 
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INTRODUCTION: 
 The obesity epidemic has been on the rise with increases in prevalence within the past 
two decades.  The World Health Organization projected that approximately 1.6 billion adults 
were overweight and 400 million adults were obese in 2005 (1).  It is currently a global problem 
in both developed and under-developed countries.  Obesity is defined as an abnormal or 
excessive fat accumulation and contributes to many adverse effects on overall health.  These may 
include: diabetes, hypertension, high cholesterol, stroke, heart disease, certain cancers, and 
arthritis (2).  A major contributor to the development of obesity is increased energy intake, 
leading to increases in body weight and body fat.  Thus regulation of food intake is a focus for 
prevention.   
Conjugated linoleic acid (CLA) has been studied for its role in the prevention or 
treatment of obesity.  CLA is a class of positional and geometric conjugated dienoic isomers of 
linoleic acid (3).  There are many isomers of CLA and the effects are isomer specific (4).  The 
trans10-cis12 isomer (t10,c12) is the active isomer possessing anti-obesogenic properties, 
whereas the cis9-trans11 isomer (c9,t11) has been suggested to exhibit anti-carcinogenic 
properties (3).   It has previously been shown that CLA has biologically beneficial effects on 
obesity including reductions in body fat, body weight, and feed intake (5).   
Feed intake can be affected by many factors at several levels, however central regulation 
of feed intake occurs at the level of the hypothalamus and specifically arcuate neurons that 
synthesize many orexigenic and anorexigenic neuropeptides.  It is unclear if CLA-altered feed 
intake involves central regulation and few studies have been conducted at the level of the 
hypothalamus.  A critical lifestyle change involves reduction of body weight and CLA has been 
suggested for its prevention of fat accumulation and weight gain.  However, the majority of 
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research has been conducted in animal models, results from human studies are inconsistent, and 
metabolic effects are poorly understood.  
 An understanding of mechanisms responsible for CLA’s effects will ensure further 
research of CLA as a potential treatment for obesity.  Therefore, the purpose of this discussion is 
to identify potential effects of CLA on body composition through energy intake and intake-
regulating hormones.  This may help to identify a possible relationship between CLA and 
appetite-controlling mechanisms. 
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CLA has been reported to elicit beneficial effects on body composition and feed intake, 
but mechanisms are still not known.  Energy homeostasis is largely controlled in the 
hypothalamus and because CLA has been shown to affect factors involved in energy 
homeostasis, it is proposed that CLA may be acting at the level of the hypothalamus in energy 
regulation.  Therefore, it is necessary to look at studies linking the beneficial effects of CLA to 
systems controlling body fat and feed intake.  
 
EFFECTS OF CLA 
Body fat: 
 Several studies have reported that CLA reduces body fat accumulation and weight gain in 
rodents (3, 5, 8, 11, 34).  Body fat was significantly decreased when CLA was provided at 0.5, 
0.75 (P < 0.05), and 1% (P < 0.01) of the diet in AKR/J mice fed high-fat diets compared to 
controls without affecting energy intake (6).  Body weight was also significantly decreased by 
day 22 in a time-course study with no effect on energy intake (6).  Increased (P < 0.01) protein 
accumulation also occurred at a dose of 1% CLA (6).  CLA reduced fat deposition in mice fed 
mixed CLA isomers or t10,c12, independent of dietary fat content (7).  It has been indicated that 
CLA may stimulate lipolysis which may contribute to the decrease in fat deposition (5).  
Decreases in body fat have been suggested to be caused by CLA-induced increases in energy 
expenditure (8).  CLA has also been found to cause apoptosis in adipocytes that may account for 
the decreases in body fat (9). 
Contrasting results were found when pigs were fed 0.83% CLA during fetal and non-fetal 
growth (10).  CLA did not alter sow feed intake during gestation or lactation, body weight, or 
backfat thickness.  In obese Zucker rats fed 0.5% CLA for 5 weeks, there was an increase in 
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inguinal fat pad weights with an increase in average fat cell size (11).  CLA was also found to 
elicit no effects in humans when a study examined changes in body composition and clinical lab 
values following CLA supplementation.  There was no change in body fat mass, weight, body 
mass index, or percent fat in subjects receiving pills containing 8 g safflower oil, 3.2 g CLA, or 
6.4 g CLA/day after 12 weeks (12).  Lean body mass was increased by 0.64 kg in the 6.4 g/day 
CLA group (P < 0.05).  However, in overweight and obese subjects receiving a placebo of 9 g 
olive oil/day or 1.7, 3.4, 5.1, or 6.8 g CLA/day of mixed isomers for 12 weeks, significant (P = 
0.05, P = 0.02) decreases in body fat occurred in the CLA group consuming 3.4 g and 6.8 g 
CLA/day, respectively (13).  A six-month change in body composition among overweight 
subjects was improved (P = 0.02) in the CLA group and body fat was significantly (P = 0.05) 
reduced (14). 
Differences in dosage and length of feeding may account for different effects in mice and 
humans.  Metabolic rate may also be an important component when comparing animals and 
humans and may explain variable results seen in body composition. Reductions in body fat are 
about 7 times higher in mice than in humans, likely due to the metabolic rate/kg body weight that 
is 7 times higher in mice (15).  Thus, the body fat-lowering effect of CLA is lower in humans 
than in mice.  However, these calculations are based on increases in energy expenditure solely 
due to body fat which may be arguable (15).  In most human studies body composition is 
indirectly measured by bioimpedance, but in rodents such as mice, body fat is measured more 
directly by weighing fat pads or tissues of interest (16).  Subjects in some human studies were 
assessed by dual energy X-ray absorptiometry that provide accurate measures of fat mass.  Body 
composition results are highly inconsistent in humans. 
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Feed Intake: 
 
 
 CLA has been shown to cause reductions in feed intake in animals (3, 4, 7, 17).  Feed 
intake was significantly reduced in mice fed 2% mixed isomer CLA preparations or 0.88% CLA 
enriched with t10,c12 (3).  The percentage of body fat in mice fed CLA was also decreased by 
70% relative to controls.  Dietary CLA reduced (P < 0.01) feed intake by 10-12% but did not 
increase energy expenditure in older mice from 10-30 weeks of age (7).  In AKJ/R mice, CLA 
fed at 1.0-1.2% mixed isomers reduced cumulative intake in the high-fat diet group by 14% and 
in the low-fat diet group by 9.6% (7). 
A few studies have reported that body fat was reduced independent of energy intake so 
this effect may not cause the decrease in body fat (6, 8, 18).  The reduced intake has not been 
associated with palatability of the CLA diet because the reduction in feed intake was not 
observed until after 3 days of CLA consumption (4).  Also, mice pair-fed the control diet at the 
intake level of CLA-fed mice did not differ in body fat from ad libitum controls, while CLA-fed 
mice were leaner (4).  Mice fed 0.5% t10,c12 CLA showed decreased body fat without changes 
in body weight or feed intake (18).  These studies indicate there may be another mechanism 
involved in CLA-induced body fat loss.  CLA (150 nmol) comprised of mixed isomers was given 
in a single injection, intracerebroventricularly (ICV) to rats and food intake was monitored for 14 
days, during which CLA decreased food intake (P < 0.05) and the decrease was maintained 
longer than rats administered linoleic acid (6-8 days vs 2-4 days, respectively) (19).  However, in 
adult women, CLA had no significant effect on energy intake, body composition, or energy 
expenditure (20). 
 Differences between the animal and human model vary greatly.  A diet containing 0.5% 
CLA is equivalent to about 56 g CLA/day in a 70 kg individual (16).  In comparison to a mouse 
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model, CLA in this human study was around 3 g/day.  A CLA dose at 3 g/day is more than 10 
times normal human daily consumption (21).  Most human studies reporting modest reductions 
in loss of body fat have included overweight or obese subjects and in this case, healthy non-
smoking women were used (12-14).  It is also worth noting that the mean age of adult subjects 
was 27-30 years and most likely are in a weight-stable stage.  In animal studies, weanling male 
mice were used in a rapidly growing stage.  However, older mice have shown decreased body fat 
in response to dietary CLA (17).  This difference in growth rates likely involves different energy 
requirements (16, 20).  In both studies, it appeared that caloric intake was carefully monitored.  
Although it is easier to control for this in mice, human subjects were confined to a metabolic 
suite where dietary intake and physical activity were controlled and held constant.  Methods of 
body composition measurement were accurate and adjustments were also made for the women’s 
menstrual cycle, body composition changes, and differences in body size (20).  Length of 
feeding period may also cause differences in energy intake where human subjects were on 
intervention diets for more than twice the amount of time in mice (15).  It may be possible that 
an increase or stabilization to baseline energy intakes can occur over time or towards the end of 
intervention.  In order to fully understand mechanisms involved in reduced energy intake, an 
understanding of how energy metabolism is regulated is necessary.   
 
 
REGULATION OF FEED INTAKE 
 The brain is the major center that regulates food intake and energy metabolism.  Within 
the brain, extensive neural networks and circuitry work to maintain energy homeostasis.  This 
neural framework allows for communication between peripheral organs to assess the metabolic 
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state.  There are three effector pathways the brain involves when adjustments are necessary: 
behavioral which controls feed intake, neuroendocrine, and autonomic nervous system which 
both control energy expenditure (22).  Disruptions in these highly controlled mechanisms may 
produce changes in energy balance and lead to obesity.   
 The hypothalamus receives and integrates signals from the periphery.  Contained within 
the hypothalamic region is the arcuate nucleus, which is able to respond to peripheral signals due 
to an anatomical location lacking a blood-brain barrier (22).  The arcuate nucleus contains two 
populations of neurons that express either orexigenic or anorexigenic neuropeptides (23).  
Orexigenic neuropeptides stiumulate feed intake and co-express neuropeptide Y (NPY) and 
agouti related peptide (AgRP).  Anorexigenic neuropeptides suppress feed intake and co-express 
pro-opiomelanocortin (POMC) and cocaine-and amphetaine-regulated transcript (CART).  
Following an input signal from hormones, arcuate neurons transduce the signals into changes in 
neuropeptides that alter food intake and energy expenditure.   
 
Neuropeptides: 
 Neuropeptide Y (NPY) is one of the most abundant neurotransmitters in the central 
nervous system and is the most potent orexigen known (22).  It selectively binds to Y1 and Y5 
NPY receptors in the hypothalamus.  Energy deprivation produced by food deprivation has been 
shown to increase the NPY mRNA content of the hypothalamus (24).  These increased levels are 
associated with decreased NPY Y5 receptor density in the hypothalamus (25).  CLA treatment 
caused an increase in NPY mRNA expression following 27 days in mice fed 0.5g/100g of 98% 
pure t10,c12 CLA (26).  In rats fed 1% CLA mixed isomers plus n-3 long-chain polyunsaturated 
fatty acids (n-3 LC-PUFA), no significant changes in NPY expression were observed (27). 
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 AgRP is a neuropeptide only synthesisized in cell bodies of NPY-containing neurons 
located in the arcuate nucleus and is co-localized with NPY in 90% of arcuate neurons. It is a 
potent selective antagonist of α-melanocyte-stimulating hormone (α-MSH) at melanocortin 
receptors, MC3R and MC4R.  AgRP mRNA expression is increased with fasting and remains 
elevated.  Activation of NPY/AgRP neurons results in stimulation of feeding and AgRP causes 
obesity when ubiquitously expressed in transgenic mice (28).  AgRP gene expression was 
increased in the arcuate nucleus of rats after supplementation with 1% CLA mixed isomer plus 
n-3 LC-PUFA (27).  This was consistent with an increase in food intake that may have resulted 
from a synergistic action of both CLA and n-3 LC-PUFA on the hypothalamus.  In Sprague-
Dawley rats, NPY and AgRP mRNA expression was decreased after ICV CLA treatment (19).  
α-MSH, derived from POMC, is the main agonist peptide ligand for MC1R, MC3R, and 
MC4R.  The production of α-MSH occurs in the arcuate nucleus and is stimulated by anorexic 
hormones leptin and insulin and inhibited by fasting (29).  It exerts inhibitory control on food 
intake and energy storage by binding the MC3R/MC4R.  Targeted disruption of MC4R has been 
reported to result in obesity in mice (29).  The effect of ICV CLA on POMC expression was 
examined in rats following an observed reduction in feed intake (19).  No alterations of POMC 
expression were found and it was concluded that CLA does not have a direct effect on arcuate 
anorexic neuropeptides.  The results open the question whether the effects of CLA are mediated 
by serum hormones involved in the regulation of feed intake. 
Hormones: 
It has been reported that the most direct mechanism by which body fat content could be 
communicated to the central nervous system would be through a molecule secreted by 
adipocytes.  Secretion could occur either in proportion to adipocyte cell size or number, resulting 
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in an aggregate satiety signal that accurately reflects total body fat storage (30).  Plasma leptin 
levels have been reported to accurately reflect the amount of body lipid across a broad range of 
body fat (31). 
Leptin is a hormone released from adipocytes that enters the circulation and crosses the 
blood brain barrier.  Once in the brain, leptin binds to receptors on POMC neurons and causes 
secretion of α-melanocyte stimulating-hormone (α-MSH), which binds to neurons expressing its 
receptor signaling a suppression of appetite (32).  It has been proposed that leptin causes a 
hyperpolarization of NPY/AgRP neurons that causes disinhibition of POMC neurons with which 
they synapse.  More directly, leptin may cause a depolarization of arcuate neurons that increases 
their firing rate (33).  This may explain leptin as an indicator of long-term energy status.  It is 
also supported by plasma leptin levels being highly correlated with adipose tissue mass (22, 33, 
45).  Increased levels of leptin result in negative energy balance and decreased levels result in 
positive energy balance (31).   
CLA-induced reductions in leptin were supported by a study on CLA’s effect on body fat 
levels and serum leptin levels in 4 week-old Sprague-Dawley rats fed 4%, 7%, and 10% fat diets 
with or without 1.5% CLA.  Serum leptin levels were reduced in the CLA-fed groups, especially 
in rats with the lowest dietary fat level (34).  This study also found significant positive 
correlations between serum leptin level and weight of white adipose tissue in control groups, but 
showed weaker association in CLA groups.  These results suggest leptin does not as accurately 
reflect the peritoneal white adipose tissue and epididymal white adipose tissue weights in CLA-
fed animals (34).  The first study to examine both free fatty acid and triacylglycerol forms of 
CLA on serum leptin concentration used male Otsuka Long-Evans Tokushima Fatty rats, an 
animal model of non-insulin-dependent diabetes mellitus that develops obesity and 
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hypertriacylglycerolemia at 6 weeks of age, insulin resistance at 12 weeks, and non-insulin-
dependent diabetes mellitus at 30 weeks.  The results showed significant reductions in serum 
leptin concentration in rats supplemented with t10,c12 CLA in addition to significant decreases 
in peritoneal, epididymal, and omental white adipose tissue weights compared to control Otsuka 
Long-Evans Tokushima Fatty rats (35).   
One study examined the effects of CLA supplementation on circulating leptin levels in 
women.  Leptin concentrations were decreased without any detectable changes in body fat mass 
(36).  Plasma t10,c12 CLA was inversely correlated with changes in body weight and serum 
leptin and correlation coefficients were stronger than the relationship among total plasma CLA 
(37). 
 Ghrelin is the only known orexigenic hormone that is produced and secreted within the 
oxyntic glands of the stomach.  It is an endogenous ligand of the growth hormone secretagogue 
receptor (GHS-R) through which many of ghrelin’s actions on feed intake are mediated (38).  
With the ability of gastricly produced ghrelin to cross the blood brain barrier and, along with 
ghrelin produced locally in the hypothalamus, it activates NPY to increase appetite.  The 
stimulatory action of ghrelin on feed intake is mediated by the NPY/AgRP pathway and most of 
the NPY neurons in the arcuate nucleus express GHS-R (39).  When ghrelin was given centrally, 
there was c-Fos activation in orexin-expressing neurons (22).  Ghrelin increased c-Fos 
expression in arcuate NPY/AgRP neurons when administered peripherally, and failed to increase 
food intake after ablation of the arcuate nucleus (40).  The rise in circulating ghrelin before a 
meal triggers a sequence of events in the arcuate nucleus where NPY and AgRP are released 
(41).  The post-prandial reduction in circulating ghrelin is regulated by caloric intake and 
glucose.  Following ingestion of fat or carbohydrate in rodents, plasma ghrelin and ghrelin 
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mRNA declined (22).  No significant changes in plasma ghrelin were observed following 
ingestion of a diet containing 1% CLA mixed isomers plus 1% n-3 long-chain polyunsaturated 
fatty acid (27).  However, GHS-R was increased in the arcuate nuclei but not significantly 
changed in the ventromedial nuclei.  Ghrelin is suggested to reflect body fat distribution and 
negatively correlate with body fat (38).  Plasma ghrelin tended to increase in obese women 
receiving 1.8 g mixed isomer CLA/day for 8 weeks, but was not significant (42). 
 Peptide YY (PYY) is secreted from the L cells of the gastrointestinal tract and rapidly 
increases postprandially when both forms of PYY, PYY1-36 and PYY3-36 are released into 
circulation (23).  Form PYY3-36 is a high affinity ligand for Y2 receptors, whereas PYY1-36 has 
affinity for Y1, Y2, Y4 and Y5 receptors (43).  Release is correlated with caloric intake with 
levels increasing 1-2 hours following a meal and staying elevated for 6 hours.  PYY3-36 inhibits 
activity of over 90% of all arcuate neurons and reverses fasting-induced c-Fos expression in the 
arcuate nucleus (44).  When NPY neuronal activity is reduced in response to PYY, it increases 
activation of POMC expression, thereby suppressing food intake.  No previous studies were 
found on the effect of CLA on PYY. 
 Insulin is secreted from the pancreatic beta cells and circulates in the blood with plasma 
levels directly proportionate to adipose tissue mass (45, 46).  Plasma insulin levels increase 
during positive energy balance and decrease during negative energy balance.  Insulin crosses the 
blood brain barrier via a saturable process yielding insulin levels in the central nervous system 
proportionate to plasma insulin (46).  Insulin receptors are widely distributed in the brain (47).  
The arcuate nucleus contains a high concentration of insulin receptors where insulin acts by 
inhibiting the NPY/AgRP neurons and stimulating the POMC neurons, resulting in a suppression 
of intake. 
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 Dietary CLA has been reported to have anti-diabetic properties (48, 49), but reports of 
CLA effects on insulin concentrations and/or responsiveness to insulin have been variable.  No 
improvements in insulin sensitivity were observed in mice fed 1% mixed isomers of CLA (50).  
It was also reported that high metabolic rate mice showed increased insulin resistance.  Increased 
insulin resistance was also observed in obese men fed 3g/day of c9,t11 CLA (51).  It has also 
been suggested that changes in plasma leptin concentrations may be affecting insulin sensitivity 
by increasing peroxidative stress (52).  However, ICV CLA treatment increased circulating leptin 
concentration and had no affect on circulating glucose and insulin levels (19).  This may be due 
to the difference between the route of CLA administration. 
 
SUMMARY 
The discrepancies observed in these studies are why researchers are hesitant to report 
CLA as an effective way to prevent obesity in humans.  Dosage, isomer composition, age, and 
gender factors should be carefully reviewed before transferring results to humans.  Exact 
mechanisms underlying CLA’s biological affects are needed in order to assist in extrapolating 
animal studies to humans.  Consequently, certain confounding variables also need to be 
addressed in studies utilizing CLA in animals. 
CLA has been found to cause anti-obesity effects including decreased body fat and 
increased energy expenditure.  Exact mechanisms are still unclear and a better understanding of 
the body fat-lowering effects and possible increases in energy expenditure by CLA is needed.  
We know the regulation of feed intake occurs in the hypothalamus and involves many hormones 
and neuropeptides associated with appetite.  It is clear CLA alters body composition by reducing 
body fat which may be mediated through the activity of intake-regulating hormones which may 
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also cause a decrease in energy intake by acting upon the hypothalamus.  More research is 
needed to understand the biological effects of CLA and possible mechanisms involving 
regulation of feed intake. 
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CHAPTER 2 
 
TITLE: EFFECTS OF CONJUATED LINOLEIC ACID ON THE REGULATION OF 
FEED INTAKE AND BODY FAT IN THE SHORT TERM1 
AUTHORS: V. Shelton*2, A. Shelton*, M. Azain†, K.M. Barnes*3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______________________  
1This study was presented at Experimental Biology 2010, Anaheim, CA [Shelton V, and KM 
Barnes. FASEB J. 24:Abst #730.5]. 
2*Division of Animal and Nutritional Sciences, West Virginia University, Morgantown, WV, 
26506; †Department of Animal and Dairy Science, University of Georgia, Athens, GA, 30602 
3Address correspondence to Kimberly M. Barnes, Division of Animal and Nutritional Sciences, 
West Virginia University, PO Box 6108, Morgantown, WV 26506; fax: 304-293-2232; phone: 
304-293-1841; email: KMBarnes@mail.wvu.edu. 
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INTRODUCTION: 
 Conjugated linoleic acid (CLA) is a group of positional and geometric isomers of linoleic 
acid containing conjugated double bonds that have been studied for their various biological 
benefits including anti-carcinogenesis, anti-atherogenesis, immune modulation, and changes in 
body composition.  Among the two active CLA isomers, c9,t11 and t10,c12, the t10,c12 isomer 
has been shown to cause reductions in adiposity and is associated with increased energy 
expenditure (26). 
 It is known that CLA decreases body fat in mice and may contribute to a reduction in 
feed intake (3-9), but the underlying mechanisms are unknown.  It has been previously reported 
that the decrease in feed intake did not occur until day 3 of 2% CLA consumption (4).  Mice also 
showed decreased body fat without any changes in body weight or feed intake (18).  These 
observations suggest the results were not due to poor palatability of the diet but rather to a 
metabolic effect.  
Energy metabolism and feed intake are regulated in the hypothalamus.  Within the 
hypothalamus, the arcuate nucleus contains neurons that express orexigenic or anorexigenic 
neuropeptides that can alter food intake by stimulating or inhibiting appetite, respectively (23).  
Few studies have involved CLA at the neurological level, but a previous experiment with rats 
found intracerebroventricularly (ICV) delivered CLA was able to inhibit food intake, and this 
related to decreased expression of orexigenic neuropeptide Y (NPY) and agouti-related protein 
(AgRP) (19).  AgRP expression was also decreased in mice fed CLA in combination with n-3 
long-chain polyunsaturated fatty acids (LC-PUFA) (27).  Dietary CLA isomers have also been 
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reported to be incorporated and metabolized in rodent brain (26).  Therefore, CLA may directly 
affect feed intake at the level of the hypothalamus.   
Alternatively, CLA is also known to alter appetite-regulating hormones, such as leptin 
(34, 35), insulin (48-51), and ghrelin (42).  Circulating levels of leptin were also increased 
following ICV injections of CLA in rats (19).  Therefore, CLA may elicit it’s anti-obesity effects 
by altering circulating hormones known to affect intake or acting directly upon energy-regulating 
neurons. The objective of this study was to determine if CLA-feeding results in altered neuronal 
activity and/or the level of intake-related hormones. 
METHODS AND PROCEDURES: 
Animal Protocol 
 Animal procedures were approved by the West Virginia University Animal Care and Use 
Committee.  Male mice (n=150; 9 wks old; ICR) were obtained from Harlan Inc. (Madison, WI) 
and individually housed in cages in a temperature-controlled room with a 12:12 h light:dark 
cycle in 2 replicates (n=75 each).  Mice were fed a base diet (modified AIN-93G) comprised of 
(g/kg): isolated soy protein (200), cornstarch (395.42), dextronized cornstarch (132), sucrose 
(100), cellulose (50), soy oil (70), AIN-93G mineral mix (35), AIN-93G vitamin mix (10), L-
cystine (2.54), L-methionine (2.54), choline bitartate (2.5).  The CLA diet was comprised of the 
same, with 33.3 g/kg soy oil replaced with CLA.  The CLA mixture provided 2% of the diet as 
mixed isomers with equal amounts of c9,t11 and t10,c12 in the diet (BASF, Ludwigshafen, 
Germany).  A 2% inclusion of CLA was used as at lower doses the reduction in feed intake is not 
consistent (10). 
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 Mice received the control diet in powder form for 1 week of adaptation.  In the second 
week, 50 mice per treatment were blocked on baseline feed intake, measured during the 
adaptation week, and randomly assigned to each diet group: CON (control diet, ad libitum); CLA 
(CLA diet, ad libitum); or PF (control diet pair-fed to the intake level of the CLA-fed mice).  
Feed intake and body weight were measured daily in the second week.  Mice were provided diet 
at 0900 and euthanized, starting at 1100.  At the end of 1, 2, 3, 5, or 7 days mice (n=10 per diet 
per day) were euthanized by overdose Pentobarbital intraperitoneal injection and a blood sample 
was collected from the heart.  These feeding durations were used as they were expected to span 
the times needed to observe reduced feed intake and body fat (4).  Liver, epididymal (EPI), and 
retroperitoneal fat pads were removed, weighed, and flash frozen in liquid nitrogen.  The body 
fat index was calculated as: [(epididymal + retroperitoneal fat pad weights)/ total body weight] x 
100.  The brain was also collected and flash frozen from half of the mice (n=5 per diet per day).  
In the other half of the mice, the remaining carcass was perfused with a 0.9% saline solution, 
followed by fixation with a 10% formalin solution.  Fixed brains were collected and stored in 
10% formalin at 4°C.   
Serum Hormones 
 Blood was centrifuged at 2000 x g for 20 minutes at 4°C.  Serum was collected and 
stored at -20°C until analysis.  Serum hormones were measured by MILLIPLEX Map mouse gut 
hormone kit (Millipore Corporation, Billerica, MA) for leptin, ghrelin, insulin, and peptide YY 
(PYY) following the manufacturer’s instructions. 
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Fatty Acid Analysis 
 Total fatty acids from liver, brain, and EPI fat pads were methylated and extracted, 
according to the method of Park and Goins (53).  Fatty acid methyl esters were analyzed by gas 
chromatography as previously reported (50).  Using a Shimadzu gas chromatograh (Model 14 A, 
Tokyo, Japan) with a flame ionization detector, heptadecanoic acid was used as an internal 
standard and fatty acid methyl esters in hexane were separated on a Supelcowax-10 fused 
capillary column under isothermal conditions.  Column temperature was 240°C, injector 
temperature was 250°C and detector temperature was 260°C (50). 
Immunohistochemistry 
Fixed brains (n=3 per diet per day) were placed in a 30% sucrose solution 24 hours prior 
to slicing.  Coronal brain slices (25 µm) were cut using a microtome (Thermo-Fisher Scientific, 
Walldorf, Germany) with a freezing stage (Physitemp Instruments Inc., Clifton, NJ) and 
maintained in well plates containing 0.5M Tris Buffer at 4ºC to prepare for 
immunohistochemistry.  Slices were placed in 3% H202 in 0.5M Tris Buffer for 30 minutes to 
remove endogenous peroxidases.  Slices were blocked with 0.5 mL Tris Buffer with 0.1% Triton 
X-100 (Tris-Tx) with 3% Normal Goat Serum (Vector Laboratories, Burlingame, CA) for 1 hour 
at room temperature.  Antigen retrieval was achieved by 0.5 mL 10mM citrate buffer, pH 6, for 
30 minutes at 85ºC for antibodies specific to AgRP and α-melanocyte stimulating hormone (α-
MSH).  For NPY, 10mM citrate buffer, pH 6, for 15 minutes at 85ºC was used.  Primary 
antibodies specific to NPY (1:3000), α-MSH (1:100), and AgRP (1:2000; Abcam, Cambridge, 
MA) diluted in 0.5 M Tris-Tx with 1% Normal Goat Serum were added for 2 hours at room 
temperature.  Secondary antibodies of anti-rabbit (1:167) and anti-guinea pig (1:167; Vector 
 20 
Laboratories, Burlingame, CA) were added for 1 hour at room temperature.  For the staining 
procedure, the VECTASTAIN Elite ABC and DAB substrate kits (Vector Laboratories, 
Burlingame, CA) were used according to the manufacturer’s instructions.  Slices were stored in 
0.5 mL 0.5 M Tris Buffer, 4°C, then mounted on glass slides with Cytoseal 60 (Richard-Allan 
Scientific, Kalamazoo, MI) and staining density was measured by densitrometry relative to 
neutral background density (images were captured using a 10x objective and 6 sub-areas were 
measured per animal and averaged; Nikon Eclipse TE2000-S, Melville, NY, Nothern Eclipse 
6.0, Empix Imaging, Ontario, Canada).  Protein expression was calculated relative to control 
mice from day 1.  Arcuate nucleus location was based off of the Allen Brain Atlas (Seattle, WA). 
Statistical Analysis 
  Data were analyzed using a two-way analysis of variance (ANOVA), testing the main 
effects of treatment and day, and the treatment x day interaction, also accounting for the effects 
of block and replicate.  F tests, least squares means, and standard error of means (SEMs) were 
calculated using the mixed procedure of SAS (SAS Institute Inc., Cary, NC).  Differences were 
determined by mean separation for pre-planned comparisons of treatment within day and day 
within treatment.  Correlations were calculated using the proc corr procedure of SAS.  For all 
tests p < 0.05 was considered significant and trends were noted when 0.05 < p < 0.10. 
RESULTS: 
Feed intake, body weight, and body composition 
Feed intake was significantly decreased in CLA-fed mice compared to CON (P < 0.05) 
on day 1, 2, 3, and 7 (Figure 1).  PF-mice also consumed less feed than controls (P < 0.05) on 
most days.  On days 1, 3, and 4, PF mice consumed less (P < 0.05) feed than CLA-fed mice, 
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because the PF mice did not consume all of the feed they were offered.  In CLA-fed mice, there 
was less feed consumed (P < 0.01) on days 2 and 3 compared to day 5, but there was no 
difference in intake between days 1 and 7.   
No differences in body weight were observed between CLA and CON mice until day 6 
and 7, when CLA-fed mice weighed less (P < 0.05, P < 0.01 respectively; Figure 2).  PF-mice 
weighed less than CON by day 3 (P < 0.01).  CON mice gained weight during the experiment as   
on days 6 and 7 they weighed significantly more (P < 0.05, P < 0.01) than days 1, 2, and 3.  
CLA-fed and PF-fed mice did not differ in weight across days.   
There were no differences in body fat index on days 1, 2, 3, and 5 (Figure 3).  Body fat 
index was less in CLA-fed mice on day 7 (P < 0.01) compared to CON.  CLA-fed mice also 
tended to be leaner than PF mice on day 7 (P=0.08).  There were no differences in body fat 
between PF and controls. 
Fatty Acid Profile 
 CLA altered the fatty acid profile of liver and adipose tissue.  These changes are 
summarized in Tables 1 and 2 respectively, with complete fatty acid profiles show in appendix 
Tables A1 and A2, respectively.  CLA isomers were incorporated in the liver in CLA-fed mice 
by day 1 (Table 1) and the concentration increased from day 1 to day 7 as CLA on day 1 was 
different from day 5 and 7 (P < 0.05).  Saturated fatty acid (SFA) concentration in CLA-fed mice 
did not differ from CON or PF until day 7, where CLA-fed mice had less SFA than PF (P < 
0.05).  Monounsaturated fatty acid (MUFA) concentration increased in CLA mice on days 2 (P < 
0.05), 5, and 7 (P < 0.01) compared to CON and PF mice.  In CLA mice, MUFA concentration 
was greater (P < 0.01) on days 5 and 7 compared to days 1 and 3.  Polyunsaturated fatty acid 
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(PUFA) concentration decreased in CLA mice on days 2, 5, and 7 (P < 0.05) compared to PF and 
CON mice. 
Both CLA isomers were incorporated in the adipose by day 2 (Table 2) and increased on 
day 3, 5, and 7 in CLA mice (P < 0.0001) compared to CON and PF.  CLA-fed mice had a 
greater concentration of CLA on days 2, 3, 5, and 7 compared to day 1.  There were no 
differences in SFA concentration.  MUFA concentration was decreased in CLA-fed mice only on 
day 3 (P < 0.05).  PUFA concentration was increased in CLA-fed mice compared to PF mice 
only on day 3 (P < 0.05).   
No incorporation of CLA occurred in the brain and CLA did not appear to alter the fatty 
acid profile (Table 3 and appendix Table A3).  In PF and CON mice, there was a greater 
concentration of SFA on day 1 compared to days 5 and 7.  On day 1, there was a lesser 
concentration of PUFA in CLA and CON mice compared to day 2, 3, 5, and 7. 
Serum hormones 
 There were no differences in serum insulin on days 1, 2, and 3 (Figure 4A).  Serum 
insulin was significantly increased in CLA-fed mice on day 5 (P  < 0.01) and day 7 (P < 0.05) 
compared to CON and PF mice.  There were no differences in serum leptin until day 7 (Figure 
4B) where it was decreased (P < 0.05) in CLA-fed mice.  Day 5 serum leptin data was not 
included due to a high number of samples that were unable to be assayed.  The only difference 
observed in serum PYY (Figure 4C) occurred on day 1, serum PYY was significantly lower (P < 
0.05) in CON than PF mice.  Serum PYY tended to be greater (P = 0.07) in CLA-fed mice on 
day 1 and lower on day 3 compared to CON mice.  Serum ghrelin was also measured but sample 
values were below the detectable range. 
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Immunohistochemistry 
 No significant differences in NPY protein expression were observed in CLA-fed mice 
compared to CON (Table 4).  On day 7, NPY was decreased in CLA mice compared to PF and 
tended to decrease in CON mice compared to PF (P < 0.05, P = 0.10 respectively).  There were 
no significant differences in AgRP, or α-MSH. 
Correlations  
No significant correlations were identified between NPY, AgRP, or α-MSH with feed 
intake (Table 5).  Serum leptin was positively correlated with both feed intake (r = 0.32; P < 
0.05) and body fat (r = 0.63; P < 0.0001).  Serum insulin was also positively correlated with 
body fat (r = 0.19; P < 0.05).  Feed intake and body fat were not significantly correlated with 
each other. 
DISCUSSION: 
 It has been previously reported that ICV CLA results in inhibition of food intake and is 
related with decreased expression of NPY and AgRP (19).  The same effects were not observed 
when dietary CLA was supplemented with n-3 LC-PUFA, as this resulted in increased 
expression of AgRP, and no change in NPY expression (27).  It was hypothesized that dietary 
CLA would alter neuropeptides and serum hormones involved in the regulation of feed intake in 
mice.  In this study, we found that CLA did not alter NPY, AgRP, or α-MSH.  CLA 
consumption did decrease serum leptin and increase serum insulin. 
 Most studies involve CLA feeding for more than a week and may result in differences in 
feed intake, incorporation into tissues, and alterations in arcuate neuropeptides.  Previously, mice 
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fed 2% mixed CLA isomers for 5 days showed reduced feed intake by day 3 (4).  In our study, 
dietary supplementation of 2% CLA decreased body fat on day 7 as CLA-fed mice were leaner 
than both CON and PF mice.  Therefore, reduced feed intake was not sufficient enough to cause 
the reduction in body fat as PF mice were not leaner than CON mice.  This same effect has been 
previously reported in mice (6, 8, 18).  
Feed intake decreased in CLA-fed mice compared to CON by day 1, which is earlier than 
previously reported at day 3 (4).  Possible mechanisms for this effect could be increased energy 
expenditure or post-ingestive metabolic effects.  CLA appeared to increase feed intake to the 
level of CON on day 5.  We investigated the possibility of a higher amount of wasted feed in 
CLA-fed mice, however this was not the case.  CLA also caused a decrease in body weight 
which is similar to previous reports (7, 17). 
 In order to confirm CLA was incorporated into tissues, we performed fatty acid analysis 
and found CLA was incorporated into liver and adipose tissue by day 1 and 2, respectively.  
Increased MUFA concentration and decreased SFA and PUFA concentrations were observed in 
the liver of CLA mice.  In adipose, differences were only seen on day 3, but MUFA and PUFA 
concentration in CLA-fed mice were not different from CON.  CLA was not incorporated in the 
brain and did not alter any other fatty acids.  Similar results were seen when CLA accumulation 
in brain tissue was not elevated in pigs fed 0.83% CLA on day 40 or 75 of gestation through day 
28 of lactation (10).  Brain tissue was collected from the cerebellum and fatty acid profile 
showed no differences from controls.  In the current study, whole brains were split longitudely 
and one-half of each brain was used for fatty acid analysis.  It has been shown that CLA inhibits 
the ∆9 desaturation of stearic acid into oleic acid (52).  We observed an increase in stearic acid 
and decrease in oleic acid concentration in the liver.  Due to the lack of CLA incorporation into 
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brain tissue, CLA appeared to have an indirect effect on feed intake.  Therefore, the next step 
was to test the possibility that CLA could alter circulating hormones associated with feed intake. 
 As expected, we observed a decrease in serum leptin in CLA-fed mice on day 7, 
corresponding with the reduction in body fat.  Furthermore, a significant correlation between 
serum leptin and body fat was found, confirming leptin as a reflection of adipose tissue mass.  
The same effects and positive correlations were found in previous studies in rats (34, 35).  Serum 
leptin was positively correlated with feed intake and body fat, however this may be a result of 
feed intake being positively correlated with body fat.  Contrasting results were reported when 
feed intake was increased and serum leptin was unchanged following CLA plus n-3 LC-PUFA 
supplementation (27), indicating leptin may not be a possible mechanism of CLA-induced feed 
intake reduction. 
We report here that serum insulin was increased in CLA-fed mice on days 5 and 7.  This 
is of interest because increases in plasma insulin concentrations have been observed, but not as 
early as 5 days this.  Plasma insulin was increased after 2 weeks of CLA-feeding in mice at 1% 
CLA (6).  In the present study, the 2% CLA dose may have had a greater effect on the insulin 
response.  Although not measured in our study, dietary CLA has resulted in a significant increase 
in fasting blood glucose levels by 2 weeks in mice (54).  When glucose levels are elevated, 
insulin secretion is stimulated (55).  Leptin is also involved in glucose maintenance via inducing 
insulin-mediated glucose disposal (56).  CLA-induced reduction of adipose tissue and reductions 
in leptin have been reported to be associated with the development of insulin resistance in mice 
(56).  In the present study, the increase in insulin occurred near the same day as the decrease in 
leptin.  It may be possible that the alterations in leptin levels were affecting insulin sensitivity.  
We hypothesized that an inhibition of NPY/AgRP neurons would result in a suppression of feed 
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intake and because insulin acts to inhibit this subpopulation of neurons, it is possible the increase 
in insulin had an effect on the tendency of NPY to be reduced in CLA-fed mice by day 7.  There 
was a slight correlation (r = 0.19, P < 0.05) between insulin and body fat, which supports the 
idea that total body fat stores and fat distribution are related to plasma insulin concentrations 
(22).   
We were unable to detect ghrelin which is most likely due to the allowance of feed 2 
hours before euthanasia.  Post-prandial reductions are seen after ingestion of fat or carbohydrate 
in rodents (22).  After 20 minutes of re-feeding from a 14 hour fast, rats showed decreased serum 
ghrelin (57).  Lack of an effect on PYY may be explained by the many factors influencing its 
release such as macronutrient composition, gastric acid, cholecystekinin, bile salts, and other 
incretin hormones (22).  It has also been noted that PYY may depend on environmental stress 
and rodents are easily stressed (22). 
 Lack of CLA incorporation into the brain correlated with no significant effect of CLA on 
NPY, AgRP, or α-MSH protein expression.  This is different from previous reports, but these 
involved mRNA expression, increased length of study, differences in dietary fat concentration, 
and/or direct route of CLA administration (19, 26).  We may have seen CLA incorporation in the 
brain and therefore, alterations in neuropeptides with a longer study.  Neuronal activity was 
detected in the arcuate nucleus but we did not quantitate other areas that may have been affected 
by CLA.  Arcuate NPY neurons respond to negative energy balance by synthesizing more NPY 
mRNA and releasing more NPY in the nearby paraventricular nucleus (PVN) (55).  No data is 
available on the effect of CLA on NPY expression in the PVN. 
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 In conclusion, mice fed CLA for 1 week exhibited reductions in feed intake, body weight, 
and body fat.  The observed reductions in feed intake were not sufficient to cause the decrease in 
body fat.  CLA-fed mice showed a decrease in serum leptin levels and this effect correlated with 
changes in body fat.  Arcuate neuropeptides were not altered by CLA feeding and may 
correspond with the lack of incorporation of CLA isomers into the brain.  Mechanisms of CLA 
action on appetite and feed regulation are still unknown, but our results indicated that CLA may 
have an indirect effect on feed intake. 
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Figure 1.  Effect of diet on feed intake.  Error bars represent standard error of the mean.  Trt, P < 
0.0001.  Day, P < 0.01.  Trt x Day, P = 0.247.  *CLA vs CON, P < 0.05.  †CON vs PF, P < 0.05.  
‡CLA vs PF, P < 0.05.  #CLA vs PF, P=0.07. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Effect of diet on body weight.  Error bars represent standard error of the mean.  Trt, P 
< 0.0001.  Day, P < 0.0001.  Trt x Day, P < 0.356.  *CLA vs CON, P < 0.05.  †CON vs PF, P < 
0.05.  ‡CLA vs PF, P < 0.05. 
*# *# *#^ #^ *# 
*† *†‡ *†‡ †‡ #† *† 
† †‡ † 
*† *†  
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Figure 3.  Effect of diet on body fat.  Body fat index = [(Retroperitoneal + Epdidymal fat pad 
weights/body weight)] x 100.  Data is shown as mean + SEM.  Trt, P = 0.089.  Day, P = 0.309.  
Trt x Day, P = 0.286.  *CLA vs CON, P < 0.01.  #CLA vs PF, P = 0.08. 
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Table 1.  Effect of diet on fatty acid profile of liver 
 
Fatty acid1   Day    P-values  
CLA2 1 2 3 5 7 Trt Day Trt x Day 
CON ND2b NDb 0.37b NDb NDb    
CLA 0.86a,w 1.59a,x 1.93a,yx 2.93a,z 2.38a,zy    
PF NDb NDb NDb NDb NDb    
SEM 0.23 0.23 0.23 0.23 0.23 <0.0001 0.006 0.001 
SFA2         
CON 37.79b,y 38.57b,zy 40.97z 39.77zy 38.95ab,zy    
CLA 38.04ab,yx 39.80ab,zx 41.29z 39.44zyx 37.02b,x    
PF 40.34a 41.02a 42.01 41.12 40.06a    
SEM 0.84 0.84 0.84 0.84 0.84 0.002 0.001 0.729 
MUFA2         
CON 19.73 20.22ab 20.28 18.25b 20.75b    
CLA 19.99x 22.44a,yx 19.91x 27.68a,zy 28.80a,z    
PF 20.06 15.73b 16.83 18.19b 17.46b    
SEM 2.00 2.00 2.00 2.00 2.00 <0.0001 0.231 0.071 
PUFA2         
CON 42.48 41.21ab 38.75 41.98a 40.30a    
CLA 41.97z 37.77b,zyx 38.80zy 32.88b,x 34.18b,yx    
PF 39.60 43.25a 41.16 40.69a 42.47a    
SEM 1.79 1.79 1.79 1.79 1.79 0.001 0.273 0.052 
 
1Fatty acids were analyzed by gas chromatography and expressed as a percent of total fatty acids.  
2CLA represents sum of both c9,t11 and t10,c12 isomers.  SFA = saturated fatty acids.  MUFA = 
monounsaturated fatty acids.  PUFA = polyunsaturated fatty acids.  ND = not detected 
abDifferent letters within a column represent differences (P < 0.05). 
xyzDifferent letters within a row represent differences (P < 0.05). 
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Table 2.  Effect of diet on fatty acid profile of adipose 
Fatty acid1   Day    P-values  
CLA2 1 2 3 5 7 Trt Day Trt x Day 
CON 0.05 0.05b 0.06b 0.04b 0.08b    
CLA 0.14x 0.75a,y 1.10a,y 1.97a,z 1.87a,z    
PF 0.07 0.08b 0.09b 0.09b 0.05b    
SEM 0.16 0.16 0.16 0.16 0.16 <0.0001 <0.0001 <0.0001 
SFA2         
CON 19.82 19.23 18.91 19.83 19.48    
CLA 20.90 19.22 20.22 20.14 19.97    
PF 20.57 19.50 20.77 19.10 19.25    
SEM 0.87 0.87 0.87 0.87 0.87 0.509 0.582 0.923 
MUFA2         
CON 36.17 35.14 36.65ab 35.33 34.00    
CLA 35.81 36.31 35.32b 37.49 36.93    
PF 36.31zy 35.91y 40.51a,z 34.99y 35.66y    
SEM 1.48 1.48 1.48 1.48 1.48 0.405 0.523 0.371 
PUFA2         
CON 44.01 45.62 44.44a 44.84 46.51    
CLA 43.29 44.47 44.46a 42.37 43.09    
PF 43.12zy 44.59z 38.71b,y 45.91z 45.09z    
SEM 1.91 1.91 1.91 1.91 1.91 0.330 0.498 0.492 
 
1Fatty acids were analyzed by gas chromatography and expressed as a percent of total fatty acids. 
2CLA represents sum of both c9,t11 and t10,c12 isomers.  SFA = saturated fatty acids.  MUFA = 
monounsaturated fatty acids.  PUFA = polyunsaturated fatty acids. 
abDifferent letters within a column represent differences (P < 0.05). 
yzDifferent letters within a row represent differences (P < 0.05). 
 
 
 
 
 
 
 
 
 
 33 
Table 3.  Effect of diet on fatty acid profile of brain 
Fatty acid1   Day    P-values  
SFA2 1 2 3 5 7 Trt Day Trt x Day 
CON 45.98z 43.92y 44.58zy 45.20y 44.18y    
CLA 45.77 44.56 44.84 45.21 44.69    
PF 47.06z 45.52zy 44.93y 44.45y 44.17y    
SEM 0.59 0.59 0.59 0.59 0.59 0.481 0.002 0.567 
MUFA2         
CON 27.67 28.34 27.32 26.58 27.71    
CLA 27.02 27.57 27.27 26.06 26.59    
PF 25.69 26.12 27.74 27.49 27.65    
SEM 0.92 0.92 0.92 0.92 0.92 0.488 0.796 0.607 
PUFA2         
CON 26.36y 27.74zy 28.10z 28.22z 28.11z    
CLA 27.21y 27.86zy 27.89zy 28.73z 28.72zy    
PF 27.26 28.37 27.33 28.05 28.19    
SEM 0.52 0.52 0.52 0.52 0.52 0.517 0.011 0.833 
 
1Fatty acids were analyzed by gas chromatography and expressed as a percent of total fatty acids. 
2SFA = saturated fatty acids.  MUFA = monounsaturated fatty acids.  PUFA = polyunsaturated 
fatty acids. 
yzDifferent letters within a row represent differences (P < 0.05). 
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Figure 4.  Effect of diet of serum hormones.  (A) Serum insulin, expressed as ng/mL.  Trt, P < 
0.01.  Day, P < 0.01.  Trt x Day, P = 0.077.  *CLA vs CON, P < 0.05.  ‡CLA vs PF, P < 0.05. 
(B) Serum leptin, expressed as ng/mL.  Trt, P = 0.154.  Day, P = 0.124.  Trt x Day, P = 0.577. 
*CLA vs CON, P < 0.05.  (C) Serum PYY, expressed as ng/mL.  Trt, P = 0.494.  Day, P < 0.05. 
Trt x Day, P = 0.123.  †CON vs PF, P < 0.05.  §CLA vs CON, P = 0.07.  Data is shown as mean 
+ SEM. 
* 
§†    § 
*‡ *‡ A 
B 
C 
 35 
Table 4.  Effect of diet on protein expression of arcuate neuropeptides1 
Day P-values 
 1 2 3 5 7 Trt Day Trt x Day 
NPY2         
    CON 95.77 99.16 51.79 94.64 106.92d    
    CLA 86.11zy 150.46z 56.75y 91.30zy 80.60d,zy    
    PF 130.95zy 141.48zy 87.86y 90.62y 167.46c,z    
    SEM 24.239 24.351 24.304 24.300 24.308 0.078 0.025 0.582 
AgRP2         
    CON 125.20 193.81 440.61 340.14 707.74    
    CLA 492.94 194.22 278.70 151.24 249.51    
    PF 470.11 224.71 749.34 264.43 161.77    
    SEM 223.53 224.57 224.14 224.10 224.17 0.733 0.549 0.543 
α-MSH2         
CON 75.77 61.50 156.09 110.88 92.32    
CLA 35.22 55.47 81.72 46.38 51.62    
PF -27.88 165.96 124.73 81.07 87.22    
SEM 61.906 62.192 62.073 62.063 62.082 0.491 0.479 0.886 
 
1Quantitation of positive staining determined by densitrometry, expressed relative to CON, d1, 
n=3/diet/day 
2NPY = Neuropeptide Y, AgRP = Agouti-related protein, α-MSH = α-melanocyte stimulating 
hormone 
cdDifferent letters within a column represent significant differences.  CON vs PF, P=0.10. 
yzDifferent letters within a row represent significant differences (P < 0.05). 
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Table 5.  Correlations 
 Feed intake1 Body fat 
 r P-value r P-value 
NPY2 -0.0711 0.643 ND2 ND 
AgRP2 0.0974 0.524 ND ND 
α-MSH2 0.0760 0.620 ND ND 
Leptin 0.3245 0.017 0.6312 < 0.0001 
Insulin 0.0421 0.610 0.1864 0.023 
PYY2 0.0403 0.647 ND ND 
Body fat 0.0986 0.230   
 
1Feed intake measured in g/day of euathanasia. 
2NPY = Neuropeptide Y, AgRP = Agouti-related protein, α-MSH = α-melanocyte stimulating 
hormone, PYY = Peptide YY, ND = not determined.  
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APPENDIX  
Table A1.  Effect of diet on fatty acid profile of liver 
 
Fatty acid1   Day    P-values  
C14:0 1 2 3 5 7 Trt Day Trt x Day 
CLA2 0.03y 0.11a,z 0.03y 0.15a,z 0.10a,z    
    CON2 0.06 0.02b 0.02 0.04b 0.03b    
    PF2 0.01 0.02b 0.01 0.03b 0.01b    
    SEM2 0.02 0.02 0.02 0.02 0.02 < 0.0001 0.031 0.008 
C16:0         
CLA 25.40ab,y 27.43zy 27.90z 28.92a,z 26.89zy    
    CON 24.71b,y 25.81zy 26.83z 25.97b,zy 25.94zy    
    PF 27.22a,zy 26.66zy 28.57z 27.58ab,zy 25.96y    
    SEM 0.72 0.72 0.72 0.72 0.72 0.003 0.006 0.369 
C16:1         
CLA 1.41 1.14 0.60 1.67 1.48    
    CON 1.89 2.41 1.69 1.38 1.19    
    PF 1.70 1.01 1.17 1.32 0.71    
    SEM 0.55 0.55 0.55 0.55 0.55 0.270 0.697 0.771 
C18:0         
CLA 12.27z 11.61b,zy 12.70z 9.61b,y 9.29b,y    
    CON 12.82 12.38ab 13.81 13.27a 12.45a    
    PF 12.97 14.12b 13.11 13.05a 13.77a    
    SEM 0.80 0.80 0.80 0.80 0.80 < 0.0001 0.210 0.136 
C18:1         
CLA 18.11a,x 20.29yx 18.51x 24.96a,zy 26.30a,z    
    CON 17.62ab 17.43 18.24 16.62b 19.18b    
    PF 18.14b 14.59 15.48 16.41b 16.48b    
    SEM 1.70 1.70 1.70 1.70 1.70 < 0.0001 0.100 0.082 
C18:2         
CLA 25.16a,z 23.58zy 23.63zy 20.44y 22.10zy    
    CON 24.36ab 24.28 25.56 24.95 26.25    
    PF 21.65b 24.44 24.24 23.49 24.25    
    SEM 1.20 1.20 1.20 1.20 1.20 0.024 0.587 0.201 
C18:3         
CLA 0.73 0.72 0.70 0.65 0.79b    
    CON 0.62 0.76 0.80 0.82 0.85a    
    PF 0.55 0.62 0.77 0.63 0.68ab    
    SEM 0.08 0.08 0.08 0.08 0.08 0.045 0.474 0.474 
CLA, c9, t11         
CLA 0.51a,x 0.95a,y 0.98a,y 1.81a,z 1.56a,z    
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    CON ND2b NDb 0.21b NDb NDb    
    PF NDb NDb NDb NDb NDb    
    SEM 0.15 0.15 0.15 0.15 0.15 < 0.0001 0.008 0.001 
CLA, t10, c12         
CLA 0.34a,w 0.64a,x 0.85a,zy 1.12a,z 0.82a,yx    
    CON NDb NDb 0.16b NDb NDb    
    PF NDb NDb NDb NDb NDb    
    SEM 0.09 0.09 0.09 0.09 0.09 < 0.0001 0.007 0.005 
C20:0         
CLA 0.28y 0.57a,z 0.62a,z 0.73a,z 0.64a,z    
    CON 0.10 0.29b 0.24b 0.31b 0.29b    
    PF 0.07 0.11b 0.15b 0.25b 0.15b    
    SEM 0.07 0.07 0.07 0.07 0.07 < 0.0001 0.001 0.565 
C20:1         
CLA 0.47a,y 1.00a,z 0.80a,zy 1.05a,z 1.02a,z    
    CON 0.21b 0.37b 0.35b 0.24b 0.38b    
    PF 0.22b 0.13b 0.17b 0.46b 0.27b    
    SEM 0.11 0.11 0.11 0.11 0.11 < 0.0001 0.027 0.117 
C20:2         
CLA 0.52 0.48 0.41 0.48 0.39    
    CON 0.36 0.50 0.28 0.39 0.45    
    PF 0.46 0.33 0.30 0.50 0.37    
    SEM 0.08 0.08 0.08 0.08 0.08 0.379 0.331 0.713 
C20:3         
CLA 1.35b,z 0.95b,y 0.99b,y 0.76b,y 0.78b,y    
    CON 1.67ab,z 1.82a,z 1.23ab,y 1.58a,z 1.88a,z    
    PF 1.70a 1.65a 1.47a 1.78a 1.73a    
    SEM 0.11 0.11 0.11 0.11 0.11 < 0.0001 0.007 0.003 
C20:4         
CLA 13.35z 10.45b,zy 11.14zy 7.62b,y 7.94b,y    
    CON 15.46z 13.86a,zy 10.51x 14.24a,z 10.87ab,y    
    PF 15.24 16.22a 14.39 14.29a 15.45b    
    SEM 1.26 1.26 1.26 1.26 1.26 < 0.0001 0.016 0.097 
C22:0         
CLA 0.06 0.09 0.04 0.03b 0.09b    
    CON 0.11zy 0.07y 0.06y 0.18a,zy 0.24a,z    
    PF 0.70y 0.10zy 0.15zy 0.21a,z 0.18ab,zy    
    SEM 0.05 0.05 0.05 0.05 0.05 0.016 0.063 0.350 
 1Fatty acids were analyzed by gas chromatography and expressed as a percent of total fatty acids. 
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2CLA = conjugated linoleic acid.  CON = control.  PF = pair-fed.  SEM = standard error of the 
mean.  ND = not detected abDifferent letters within a column represent differences (P < 0.05). wxyzDifferent letters within a row represent differences (P < 0.05). 
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Table A2.  Effect of diet on fatty acid profile of adipose 
Fatty acid1   Day    P-values  
C14:0 1 2 3 5 7 Trt Day Trt x Day 
CLA2 0.52 0.45 0.47 0.44 0.43    
    CON2 0.51 0.49 0.51 0.52 0.53    
    PF2 0.52 0.50 0.52 0.44 0.52    
    SEM2 0.04 0.04 0.04 0.04 0.04 0.108 0.692 0.834 
C16:0         
CLA 18.30 16.81 17.46 17.32 17.36    
    CON 17.50 16.89 16.73 17.45 16.94    
    PF 18.10 17.07 18.24 16.60 17.17    
    SEM 0.77 0.77 0.77 0.77 0.77 0.711 0.521 0.939 
C16:1         
CLA 3.63 3.53 3.11b 3.44 3.60    
    CON 4.14 4.01 4.52a 4.38 3.69    
    PF 3.82zy 3.66y 4.85a,z 3.39y 4.20zy    
    SEM 0.38 0.38 0.38 0.38 0.38 0.019 0.649 0.263 
C18:0         
CLA 2.02 1.80 2.21a 2.32a 2.13a    
    CON 1.71 1.80 1.62b 1.81b 1.94ab    
    PF 1.92zy 1.88zy 1.95ab,zy 2.01ab,z 1.52b,y    
    SEM 0.16 0.16 0.16 0.16 0.16 0.005 0.605 0.343 
C18:1         
CLA 31.61 32.27 31.61b 33.42 32.71    
    CON 31.59 30.60 31.68b 30.44 29.67    
    PF 31.88zy 31.70zy 35.09a,z 31.06b,y 30.94b,y    
    SEM 1.20 1.20 1.20 1.20 1.20 0.098 0.518 0.410 
C18:2         
CLA 40.00 40.96 40.80a 38.28 39.10    
    CON 40.83 42.30 41.35b 40.83 42.60    
    PF 39.76zy 41.41z 35.17ab,y 42.71z 41.69z    
    SEM 2.01 2.01 2.01 2.01 2.01 0.348 0.623 0.438 
C18:3         
CLA 2.60z 2.38zy 2.20b,zy 1.77b,y 1.78b,y    
    CON 2.65zy 2.83zy 2.61ab,y 3.25a,z 3.29a,z    
    PF 2.73 2.63 3.02a 2.66a 2.90a    
    SEM 0.21 0.21 0.21 0.21 0.21 < 0.0001 0.980 0.009 
CLA, c9, t11         
CLA 0.10x 0.42a,y 0.60a,y 1.07a,z 1.05a,z    
    CON 0.04 0.05b 0.06b 0.04b 0.06b    
    PF 0.06 0.07b 0.08b 0.09b 0.04b    
    SEM 0.08 0.08 0.08 0.08 0.08 < 0.0001 < 0.0001 < 0.0001 
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CLA, t10, c12         
CLA 0.03x 0.33a,y 0.51a,y 0.89a,z 0.82a,z    
    CON ND2 NDb 0.01b NDb 0.02b    
    PF 0.01 0.01b 0.02b 0.01b NDb    
    SEM 0.08 0.08 0.08 0.08 0.08 < 0.0001 0.000 < 0.0001 
C20:0         
CLA 0.05b 0.06 0.07 0.05 0.07    
    CON 0.13a,z 0.05y 0.04y 0.04y 0.06zy    
    PF 0.06ab 0.05 0.06 0.05 0.03    
    SEM 0.03 0.03 0.03 0.03 0.03 0.596 0.678 0.607 
C20:1         
CLA 0.55a 0.51 0.60 0.63 0.62    
    CON 0.44b,y 0.54zy 0.45y 0.51zy 0.64z    
    PF 0.62a 0.55
 0.57 0.53 0.52    
    SEM 0.05 0.05 0.05 0.05 0.05 0.169 0.606 0.172 
C20:2         
CLA 0.16z 0.12zy 0.12zy 0.04b,y 0.05b,y    
    CON 0.09 0.13 0.13 0.16a 0.17a    
    PF 0.16 0.13 0.11 0.12ab 0.13ab    
    SEM 0.03 0.03 0.03 0.03 0.03 0.113 0.862 0.083 
C20:3         
CLA 0.11z 0.09zy 0.09zy 0.04b,y 0.05b,zy    
    CON 0.13 0.11 0.09 0.15a,z 0.16a,z    
    PF 0.13 0.11 0.11 0.09ab 0.11ab    
    SEM 0.02 0.02 0.02 0.02 0.02 0.005 0.565 0.196 
C20:4         
CLA 0.28 0.17 0.14 0.26ab 0.24    
    CON 0.26zy 0.20y 0.20y 0.39a,z 0.22y    
    PF 0.26 0.23 0.22 0.24b 0.22    
    SEM 0.05 0.05 0.05 0.05 0.05 0.556 0.053 0.591  1Fatty acids were analyzed by gas chromatography and expressed as a percent of total fatty acids. 
2CLA = conjugated linoleic acid.  CON = control.  PF = pair-fed.  SEM = standard error of the 
mean.  ND = not detected abDifferent letters within a column represent differences (P < 0.05). xyzDifferent letters within a row represent differences (P < 0.05). 
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Table A3.  Effect of diet on fatty acid profile on brain 
Fatty acid1   Day    P-values  
C16:0 1 2 3 5 7 Trt Day Trt x Day 
CLA2 24.03 23.07 23.20 23.44 23.17    
    CON2 23.97 22.94 23.27 23.40 22.76    
    PF2 24.52z 23.70zy 22.89y 22.98y 22.75y    
    SEM2 0.45 0.45 0.45 0.45 0.45 0.932 0.012 0.824 
C18:0         
CLA 21.74 21.49 21.63 21.77 21.51    
    CON 22.00z 20.99y 21.21zy 21.80zy 21.42zy    
    PF 22.53z 21.81zy 22.04zy 21.47y 21.42y    
    SEM 0.32 0.32 0.32 0.32 0.32 0.181 0.088 0.497 
C18:1         
CLA 25.40 25.30 25.32 24.84 25.62    
    CON 25.85 25.85 24.96 25.20 25.48    
    PF 25.15 23.78 25.26 25.26 25.41    
    SEM 0.73 0.73 0.73 0.73 0.73 0.552 0.876 0.853 
C18:2         
CLA 0.75 0.76 0.82 0.78 0.74    
    CON 0.91z 0.82zy 0.90z 0.64y 0.76zy    
    PF 0.83 0.88 0.84 0.79 0.84    
    SEM 0.09 0.09 0.09 0.09 0.09 0.454 0.503 0.821 
C20:1         
CLA 1.62 2.27 1.95 1.22 0.97    
    CON 1.81 2.49 2.36 1.38 2.23    
    PF 0.53y 2.34z 2.48z 2.23z 2.24z    
    SEM  0.46  0.46  0.46  0.46  0.46 0.279 0.041 0.263 
C20:4         
CLA 10.28 10.11 9.74 10.07 10.02    
    CON 10.45 9.82 9.99 10.01 9.82    
    PF 10.80z 10.19zy 9.64y 10.13zy 9.94y    
    SEM 0.27 0.27 0.27 0.27 0.27 0.740 0.023 0.869 
C22:4         
CLA 1.78a,y 2.98z 2.71z 3.01z 2.99z    
CON 0.60b,y 3.02z 2.87z 2.83z 3.08z    
PF 0.56b,y 3.02z 2.99z 2.88z 2.94z    
SEM   0.30   0.30   0.30   0.30   0.30 0.420 < 0.0001 0.295 
C22:6         
CLA 14.40zy 14.01y 14.62zy 14.87z 14.96z    
CON 14.39 14.08 14.34 14.74 14.46    
PF 15.06z 14.27zy 13.86y 14.25y 14.46zy    
SEM 0.28 0.28 0.28 0.28 0.28 0.492 0.086 0.203 
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1Fatty acids were analyzed by gas chromatography and expressed as a percent of total fatty acids. 
2CLA = conjugated linoleic acid.  CON = control.  PF = pair-fed.  SEM = standard error of the 
mean.  ND = not detected 
abDifferent letters within a column represent differences (P < 0.05). 
yzDifferent letters within a row represent differences (P < 0.05). 
 
 
 
 
 
 
 
